



May 19, 2026

Corporate name: SHOFU INC.
Representative: Tetsuo Takami
Representative Director, President & COO
Listing: Tokyo Stock Exchange (Prime Market)
Code number: 7979
Contact: Fumitaka Yamazaki
Director, Senior Managing Executive Officer
Corporate Planning
(TEL: +81-75-561-1112)

Notice Regarding Investment in Toregem BioPharma Co., Ltd.

SHOFU INC. (Head Office: Kyoto, Japan; Representative Director and President Tetsuo Takami, the “Company”) hereby announces that it has decided to subscribe to a third party allotment new shares and make an investment in Toregem BioPharma Co., Ltd. (Head Office: Kyoto, Japan; Representative Director and President Honoka Kiso, “Toregem”), a Kyoto University-originated startup engaged in research and development of regenerative medicine in the field of dentistry.

Through this investment, the Company aims to build a medium-to-long-term strategic partnership with Toregem.

1. Purpose of the share acquisition

In the field of dentistry, in addition to conventional approaches centered on prosthodontic treatment, the development of regenerative medicine technology is expected to create new treatment options.

Toregem is focusing on USAG-1, a protein that inhibits tooth development, and are engaged in research and development of antibody drugs that promote tooth regeneration. Toregem’s lead development candidate, TRG035 (humanized anti-USAG-1 antibody), is undergoing clinical trials for congenital edentulism and has been designated as an orphan drug. Toregem also envisions expansion of target diseases and indications in the future.

In anticipation of changes in the future structure of dental care, the Company has decided to make this investment as a strategic investment for future growth, not for the purpose of short-term earnings, from the perspective of early involvement in the field of regenerative medicine, complementarity with adjacent businesses including the fields of diagnosis, prevention and maintenance, and acquisition of knowledge in medical/dental cooperation and new technology development.

2. Overview of Toregem

Company name	Toregem BioPharma Co., Ltd.
Location	448-5 Kajii-cho, Kamigyo-ku, Kyoto City JAPAN
Founding	May 12, 2020
Representative Director	Honoka KISO
Business	R&D of regenerative medicine for dentistry and the oral cavity

3. Overview of the investment

Investee: Toregem BioPharma Co., Ltd.

Investment method: Subscription to a third-party allotment of new shares

Investment amount: Undisclosed



Shares acquired: Class D preferred shares

Payment date: May 15, 2026

4. Future outlook

Through the collaboration with Toregem, we will consider the possibility of collaboration in the fields of diagnosis, prevention, and progress management surrounding tooth regeneration treatment.

In addition, we will contribute to dental care around the world by conducting joint studies on technologies and devices that contribute to the creation of new therapeutic value in the field of dental care and by exploring future business opportunities, including cooperation in medical and dental fields.

(Note) This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.